Categories
COVID-19 Government Guidelines Medicine & Health

New Covid-19 variant ‘Pirola’ or BA.2.86 is different from others, Coronavirologist shares 5 important facts

Coronavirologist Dr Pavithra Venkatagopalan says that Pirola or BA.2.86 variant has as many changes as Omicron had from Delta.

Coronavirus has been changing and evolving ever since it was first discovered in the year 2019 and became a global concern in a matter of few months. The original Covid strain soon turned into the ‘deadly Delta’ taking a huge toll across the globe. With massive vaccination drive all across India and other parts of the world, and the efforts of Covid warriors including scientists, medical practitioners, doctors, nurses, this health crisis could be curbed. As Covid transformed into a way milder Omicron variant, the symptoms became less severe and the fears regarding the spread of the virus eased.

Coronavirologist Dr Pavithra Venkatagopalan says that Pirola or BA.2.86 variant that has been increasing cases in US, UK, China and other countries, seems to have as many changes as Omicron had from Delta. The coronavirologist also added that we are yet to understand the severity of the strain and the impact of the new mutations the virus has.

Dr Pavithra Venkatagopalan, corona-virologist and Covid awareness specialist at Rotary Club of Madras NextGen in a telephonic interview with HT Digital shares 5 important facts about Pirola or BA.2.86 that everyone wants to know.

New Covid-19 variant ‘Pirola’ or BA.2.86 is different from others, Coronavirologist shares 5 important facts

1. Pirola or BA.2.86 has 35 new mutations

All viruses change with time including SARS-Cov2. These changes are designated as variant depending on how different they are based on their genetic sequence as compared to the previous variant. One of the recent variants that has been discovered is BA 2.86. This variant is interesting because it has a lot of 35 new mutations that sets it apart from previously known prevalent Covid variants.

2. BA.2.86 has limited samples so severity is unknown

We don’t know the severity of this strain because worldwide we have received just 9 samples. This does not mean that there are only 9 cases. This simply means that all the Covid virus cases that were tested for the genetic sequence, 9 have been identified in different parts of the world suggesting it’s prevalent worldwide.

3. Pirola may not be really new

It is important to remember that just because we have detected a variant now doesn’t mean it’s new. Covid is no longer considered a global crisis. The efforts put into genetically sequencing the virus have also come down, so we don’t know for how long this variant has been travelling undetected. There is no evidence to suggest that this variant is a lot more severe in terms of symptoms they cause or how quickly they transmit from each other simply because we have just 9 identified sequence samples which simply don’t know about genetic makeup of other variants that may be spreading.

4. Why BA.2.86 is a variant of interest

It is variant of interest because it has around 30 genetic changes from its parent which is B82 variant which is dubbed as omicron in the media. Omicron was designated as a different variant from its ancestral Covid variant which was delta which was the B 1.617.8.2. This seems to have as many changes as Omicron had from Delta.

5. Will previous vaccines work to prevent Pirola?

Whether the previous vaccines will work or not, we will have to wait and see because we do not know how long this variant has been getting transmitted. All those people who have had Covid and had more global vaccines and not specific RNA vaccines are expected to have some level of leverage. These companies have been updating their vaccines as the virus is evolving. If you have those vaccines in access and are eligible to take those vaccines, please continue to take them as advised by your local health body.

Read more at-https://shorturl.at/bfisY

Categories
COVID-19 Government Guidelines Medical Equipments Medicine & Health

ICMR study: Who’s more at risk after leaving the hospital with COVID-19?

The Indian Council of Medical Research (ICMR) recently published a research paper highlighting varying vulnerability to post-discharge mortality in COVID-19 cases. The study highlights three risk factors for death after discharge while also highlighting the importance of vaccinating prior to contracting the coronavirus.

“Post-discharge mortality” refers to the occurrence of death after a person has been discharged from a medical facility, such as a hospital, following treatment for a specific medical condition.
The new ICMR study, titled “Determinants of post-discharge mortality among hospitalized COVID-19 patients,” identifies three prominent risk factors associated with post-discharge mortality among COVID-19 survivors. People over the age of 40, men with co-morbidities and individuals who endured moderate to severe COVID-19 cases have a more pronounced risk of post-charge mortality.
On a more positive note, the study reveals that those who received at least one dose of the SARS-CoV-2 vaccine before contracting the virus experienced a 60 percent reduction in the risk of post-discharge mortality.
The research accumulated results from 14,419 participants hailing from 31 hospitals nationwide, who were followed up for a period ranging from four weeks to one-year post-discharge. 942 individuals (6.5 percent) had succumbed, while the remaining 93.5 percent were documented as alive during the year-long follow-up.
“Similar trends were seen in participants, 18-45 years of age,” the ICMR team said.
ICMR study: Who's more at risk after leaving the hospital with COVID-19?
While the findings offer valuable insights, the study acknowledges limitations stemming from telephonic follow-ups, which could lead to symptom underreporting. Also, the study’s focus was exclusively on hospitalised COVID-19 patients, which restricts the generalisability of the conclusions to the broader population.
In parallel to this study, the ICMR is currently overseeing a multicentric hospital-based matched case-control study, which seeks to investigate the impact of the COVID-19 vaccine on heart attacks among individuals aged 18–45 years in India.
Furthermore, the ICMR is actively researching factors associated with sudden deaths among adults aged 18–45 years in India.
Meanwhile, PK Mishra, the principal secretary to Prime Minister Narendra Modi, on Monday, held a high-level meeting to review the global and national COVID-19 situation in view of the new variants, Pirola (BA.2.86) and Eris (EG.5).
During the meeting, Mishra highlighted the need for states to monitor trends of influenza-like illnesses despite the stable COVID-19 situation, and prepared healthcare systems. He also focused on the need to send enough samples for genome sequencing.
Read more at-https://tinyurl.com/v7zjzezx
Categories
COVID-19 Government Guidelines Medical Equipments Medicine & Health

Dengue outbreaks: 9 reasons why dengue cases are getting more severe; what role does global warming play

Prenatal genetic testing is now quite affordable and being increasingly used for improving reproductive outcomes in every pregnant woman as genetic testing prenatally, a.k.a before birth has given the opportunity to screen for a variety of severe genetic abnormalities and take necessary action in time. This helps in preventing the birth of children with genetic birth defects thus saving financial and emotional burden on the family.

With the advent of such testing, couples are now able to obtain information about genetic disorders of their foetus and make an informed decision about the same. In an interview with HT Lifestyle, Dr Veronica Arora, Assistant Consultant at Institute of Medical Genetics and Genomics at Sir Ganga Ram Hospital, revealed, “Genetic testing is not offered to obtain information about the foetus to predict non-disease-related traits. Such practice is strongly condemned. Some common myths about prenatal genetic testing include that it is only done for older women, it is very expensive, it is only done for Down syndrome, not required in the absence of family history, or done only for high-risk women.”

Highlighting that testing in the prenatal scenario includes non-invasive and invasive genetic tests, she elaborated –

  • Non-invasive tests: Biochemical markers, non-invasive prenatal screening are those which are performed on the blood of the mother. Testing for common aneuploidies and thalassemia is included in this category, and these are offered universally to all pregnant women.
  • Invasive genetic testing: Amniocentesis or Chorionic villus sampling is limited to fetuses at risk of having a genetic disorder. This includes those at risk due to positive family history, advanced maternal age, positive screening tests for aneuploidies or ultrasound abnormalities.

Dengue outbreaks: 9 reasons why dengue cases are getting more severe; what role does global warming play

Addressing myths on prenatal genetic testing, Dr Ramesh Hariharan, CEO and Co-Founder of Strand Life Sciences, shared –

  1. Prenatal genetic testing can help determine if the baby, while still in the mother’s womb, has a genetic abnormality.
  2. Pre-natal testing need not be invasive for the baby; some abnormalities in the baby can be detected from the mother’s blood; these include large scale genomic abnormalities that cause Down’s syndrome.
  3. Not all abnormalities can be easily detected from the mother’s blood though, particularly finer genetic abnormalities, those may need a procedure called amniocentesis or CVS to access cells from the baby.
  4. All positive results detected from mother’s blood should be confirmed by an amnio or CVS.

Read more at-https://shorturl.at/eoSZ7

Categories
COVID-19 Government Guidelines Medical Equipments

Covid-19 poses high chances of death to people above 40: ICMR study

The latest research paper released by Indian Council of Medical Research (ICMR) has revealed that covid-19 people above 40 years of age, men with co-morbidities and those individuals who suffered moderate to severe covid-19 were associated with higher odds of post-discharge one-year mortality, whereas 60% protection was conferred by vaccination before the covid-19 infection.

Of the 14,419 participants from 31 hospitals across the country who were followed up at least once between four weeks and one year post discharge, 942 (6.5%) had died and the remaining (93.5%) were reported alive at any contact during one year of follow up.

The study titled– “Determinants of post discharge mortality among hospitalized covid-19 patients: Nested matched case-control analyses from the National Clinical Registry for covid-19″ has now been published in the latest issue of Indian Journal of Medical Research (IJMR) was conducted by the National Clinical Registry for covid-19 study team.

“Participants who had received at least one dose of the anti-SARS-CoV-2 vaccine before their covid-19 infection had a lower risk of post-discharge mortality,” the study said.

Covid-19 poses high chances of death to people above 40: ICMR study

“Emphasis was put on the 18-45 years of age to understand the factors associated with post discharge death in young adults. Factors associated with death in them after discharge were similar to the ones observed in other age brackets. Prior anti-covid-19 vaccination did lend some protection against all-cause post discharge death in this age group, although this cannot be claimed conclusively as the association was not statistically significant,” the study said.

The limitations of the current investigation include reliance on telephonic follow-up, which could have led to underreporting of the symptoms. The present analyses only included patients who were hospitalized due to covid-19, and consequently, the findings cannot be generalized to all patients who had covid-19, the study stated. In addition to this, ICMR is also conducting a multicentric hospital-based matched case-control study   on the effect of covid-19 vaccine on heart attack among 18–45-year-old population in India in 2022 and on factors associated with sudden deaths among adults aged 18–45 years in India.

Read more at-https://t.ly/KwMYe

Categories
COVID-19 Government Guidelines Medical Equipments Medical Updates

New Covid variant Eris symptoms appear a week before positive test? Know all about this ‘pre-Covid’ phenomenon

Experts say this could be because when a person contracts a virus, it takes time for it to replicate within the body to trigger noticeable symptoms.

New Covid variant EG.5 has been spreading fast in different parts of the world and while the strain is good at escaping immunity, the symptoms remain mild, and experts say it doesn’t pose a significant threat. EG.5 has been declared as a variant of interest and will be monitored for its mutations. The strain may become dominant in many countries with its rapid spread. As the Eris and other Omicron variants are being detected, people are also reporting a ‘pre-Covid’ phenomenon that was even being reported in the initial days of pandemic. This means that people are showing signs of Covid even with a negative test and upon being tested again after a week or so, the result comes positive.

Experts say this is because when a person contracts a virus, such as Covid-19, it takes time for the virus to replicate within the body to trigger noticeable symptoms. The initial test comes negative due to low viral load and the same increases with each passing day. If you too are facing this ‘pre-Covid’ phenomenon, get tested again after a week for correct diagnosis.

The incubation period effect

“This phenomenon can be attributed to the virus’s incubation period. When a person contracts a virus, such as Covid-19, it takes time for the virus to replicate within the body to levels that trigger noticeable symptoms. This period between exposure to the virus and the appearance of symptoms is known as the incubation period. Eris is one of the two latest sub-variants of Corona virus. The symptoms of Eris variant start about a week before it could be detected by tests. The symptoms are nearly the same as those of Covid illness,” says Dr Anurag Saxena, HOD-Internal Medicine, Primus Super Speciality Hospital.

“In the case of Eris and similar illnesses, symptoms may manifest roughly a week before a positive test because the virus or pathogen has been present in the body long enough to cause noticeable symptoms, but it might still take a little more time for the viral load to reach a level detectable by the testing methods in use,” adds Dr Saxena.

New Covid variant Eris symptoms appear a week before positive test? Know all about this 'pre-Covid' phenomenon

Go for RT-PCR tests

“In some patients, they continue to test negative for Covid illness, because they don’t have it. In some cases, initial tests can be negative due to low viral load initially, i.e., load below the limit of detection of that particular test. In such cases, repeating a test after few days usually helps to confirm the diagnosis. In other patient, use of rapid antigen tests, improper sampling technique (when performed by self) etc. can be cause of negative result despite having Covid illness. In such cases, RT-PCR tests, a more accurate test than rapid antigen tests, should be performed, and sampling performed preferably by trained personnel. As of now, there is very limited data to suggest any significant difference compared to previously circulating variants with respect to transmissibility, immune evasiveness, severity, diagnostic modalities, or response to available treatment. Furthermore, more robust, large cohort-based data is needed, on viral dynamics of new emerging variants, and performance characteristics of various tests in such scenarios to ascertain such phenomenon and its plausible explanation,” says Dr Rohit Garg, Consultant, Dept of Infectious Disease, Amrita Hospital, Faridabad.

“Symptoms such as nasal congestion, sneezing, cough, fever and fatigue is commonly seen in the ‘pre COVID’ period. This can last upto first 7 days of the infection. It is seen with Eris variant as the transmissibility of this virus is higher than the previous variants. However, there is no need to panic and it becomes imperative to follow Covid appropriate behaviour, especially hand hygiene, during the monsoon season when the rate of airborne and droplet infections are already high,” says Dr Charu Dutt Arora, Infectious Disease Specialist, Consultant Physician, AmeriHealth, Asian Hospital.

“Understanding this timeline helps in both managing the illness and preventing further transmission, as individuals with symptoms can take appropriate precautions and seek medical attention promptly, reducing the risk of spreading the illness to others,” says Dr Saxena.

Eris symptoms

Dr Saibal Chakravorty, Senior Consultant – Internal Medicine, Metro Hospital Noida says the symptoms of the new variant as of now are same as we have seen and witnessed previously, though more research on this is being done.

As per limited evidence, the symptoms are:

  • Cough
  • High Fever
  • Severe Headache
  • Body ache
  • Weakness and Fatigue
  • Decreased Appetite

Read more at-https://shorturl.at/ceptO

Categories
COVID-19 Government Guidelines Medical Equipments Medical Updates

New Covid variants Eris vs BA 2.86: Is the one scarier than the other? Know difference between symptoms

Eris vs BA 2.86, both are variants from XBB lineage which is a descendent of Omicron. Here’s what to know about their symptoms are transmissibility.

Even as pandemic threat subsides, Covid-19 virus continues to evolve and most recently two Covid variants namely Eris or EG.5 and BA 2.86 have been increasing the caseload in UK, China and other countries. While Covid symptoms seem to have become milder with course of time and newer variants, the mutations in the spike protein have increased due to which they are becoming good at escaping immunity and also infecting people faster. While EG.5 has been declared variant of interest, BA 2.86 is being called variant under monitoring by WHO. BA 2.86 is said to be highly mutated and this particular strain has some new symptoms associated with it, says Dr Pavithra Venkatagopalan, corona-virologist and Covid awareness specialist at Rotary Club of Madras NextGen in a conversation with HT Digital.

Why newer variants of Covid-19 are evolving

“The virus causing Covid-19 has continued to evolve from the time it was identified in December 2019. Over these last 3-3.5 years, we have seen lot of different variants come and go and each of these variants have lot of properties in common and some other varying ones. One of the common properties include the transmission via droplets. This has not changed in any of the variants that have come so far. We have seen the beta, gamma, delta, and Omicron variants. All these variants are causing Covid-19. What happens is when people with different symptoms of Covid-are identified, their sample is collected and sent for sequencing. Sequencing is a simple way of understanding what this virus is made of. Each of these variants behave differently because they have different genetic sequence changes,” says Dr Pavithra.

Eris or EG.5 and BA 2.86 are the two variants that have been making headlines as they are spreading very fast and are able to evade vaccine immunity or immunity acquired from an infection. Dr Pavithra explains the difference between the two strains.

Difference between EG.5 and BA 2.86 Covid variants

“We have a new ‘variant of interest’ and another fresh ‘variant under monitoring’ at this point – one is Eris EG.5 and the other is BA2.86. Both of these are variants from XBB lineage which is a descendent of Omicron. The difference is we have identified more of Eris cases worldwide which seems to have high rates of transmissibility. Whether we have more cases of BA2.86 or not, we have to see,” says Dr Pavithra.

New Covid variants Eris vs BA 2.86: Is the one scarier than the other? Know difference between symptoms

New Covid symptoms of BA 2.86

Dr Pavithra says BA 2.86 has few new extra symptoms which seem to be associated with this variant infection.

“People are getting rashes, there is some eye redness, there is some cases of diarrhoea,” she says.

Fever, cough, shortness of breath, fatigue, muscle aches, headache, loss of taste and smell, and sore throat are symptoms that are being reported with Eris infection.

Does this make BA 2.86 less or scarier? These aren’t overly surprising symptoms, but it’s a sudden change that shows the virus is continuously evolving, says Dr Pavithra.

New vaccines to fight new variants

“BA 2.86 has 36 new mutations that may allow it to evade the antibodies we already have. In the US and Germany they are upgrading PFizer and Moderna against the new strains. This doesn’t mean that the shots we took earlier are not effective, but they may be less effective. The battle between our immune system and the virus will be constantly faced as virus evolves. If not vaccinated, we must make sure you get it, especially if it’s been over a year.

Read more at-https://shorturl.at/lxEKY

Categories
Government Guidelines Medical Equipments Medical Updates

Cancer-infecting virus warms up cold tumors, boosts immunotherapy: Research

The study states that cancer-infecting viruses can boost immunity of the body and support immunotherapy.

According to recent research published in the Journal of Experimental Medicine, equipping cancer-infecting viruses with tumor-inhibiting genetic cargo boosts the immune system and supports immunotherapy in reducing or totally eradicating aggressive tumours in mice. The findings pave the path for clinical studies combining oncolytic viruses with immunotherapy.

Oncolytic viruses are genetically modified viruses that target rapidly dividing tumor cells while avoiding normal cells.

Oncolytic viruses were originally designed to directly kill cancer cells, but researchers later noticed that they also stimulated the immune system, suggesting that they could be coupled with other cancer therapies such as immune checkpoint inhibitors, which remove the brakes on the immune system so that T cells can recognize and attack tumors.

“Immune checkpoint inhibitors work only in ‘hot’ tumors, which have already been infiltrated by T cells,” said senior author Greg Delgoffe, Ph.D., associate professor of immunology at Pitt’s School of Medicine and director of the Tumor Microenvironment Center at UPMC Hillman Cancer Center. “Oncolytic viruses can help ‘warm up’ cold tumors, so they have amazing potential to work hand-in-hand with immunotherapy, but they haven’t yet lived up to that promise.”

According to lead author Kristin DePeaux, a graduate student in Delgoffe’s lab, the problem is that many patients’ tumors do not respond to oncolytic viruses.

Cancer-infecting virus warms up cold tumors, boosts immunotherapy: Research

“There’s been a lot of interesting lab-based research on oncolytic viruses, but it hasn’t translated to the clinic,” she said. “We wanted to understand the mechanisms behind tumor resistance to these viruses to see what we can do to help patients.”

The researchers first developed a head-and-neck squamous cell carcinoma (HNSCC) cell line that is very sensitive to an oncolytic virus called vaccinia. Tumors injected with the virus regress after a single dose. They also developed a second cancer cell line that was otherwise identical but resistant to vaccinia.

After injecting both types of cells into mice and comparing immunological differences in the tumors that grew, they found that resistance to vaccinia was driven by high levels of a signaling protein called TGF-β, which is known to promote cancer growth by suppressing the immune environment.

Partnering with Andrew Hinck, Ph.D., professor of structural biology at Pitt, the team next engineered vaccinia to carry a gene encoding a TGF-β inhibitor.

“TGF-β inhibitors are very potent. They’ve been tried in the clinic, but they’re usually toxic because they’re delivered systemically,” said Delgoffe. “What’s really cool about using oncolytic viruses is that they deliver this cargo directly to the tumor microenvironment, so it’s very targeted and a much safer way to treat.”

When they injected the modified vaccinia into mice with vaccinia-resistant HNSCC, the tumors shrank or, in about 50% of mice, completely cleared, greatly increasing survival compared to animals that received the control virus, which didn’t carry the TGF-β inhibitor. Importantly, the treatment didn’t cause any autoimmune or toxicity-related side effects.

Next, the researchers tested whether the modified viruses could work similarly in a highly aggressive form of melanoma that is resistant to anti-PD1 immune checkpoint inhibitors. Animals that received no treatment, anti-PD1 or control vaccinia all died within about 24 days, while about 20% of those that received the modified virus had complete clearance of the tumor.

The most dramatic results occurred when modified vaccinia was combined with anti-PD1. In 67% of mice, tumors completely cleared, and survival was greatly extended.

Delgoffe and his team hope that a version of their modified vaccinia virus, which they’ve licensed to Kalivir Immunotherapeutics, could soon be ready to test in human clinical trials as an adjuvant for immune checkpoint inhibitors in patients who haven’t responded to these immunotherapies.

Read more at-https://shorturl.at/pxCZ7

Categories
COVID-19 Government Guidelines Medical Equipments Medical Updates

COVID variant EG.5: What we know about Eris

The WHO says new omicron subvariant EG.5 Eris is a virus of interest. It’s reignited talk about vaccines and speculation about a return of the pandemic.

After more than three years of the COVID-19 pandemic, the World Health Organization ended the global public health emergency on May 5, 2023. But at the same time, WHO Director-General, Tedros Adhanom Ghebreyesus noted that SARS-CoV-2, the virus that leads to COVID, had not been fully defeated, that it continued to circulate in the world and that we could still see the emergence of new and more dangerous variants.

And that’s where we are now: there is a new COVID variant: EG.5, also known as Eris. We just don’t know whether it’s more dangerous than previous variants yet.

The WHO has classified the EG.5 as a Variant of Interest (VOI). At time of writing, it is not a Variant of Concern (VOC), which is one step worse that a Variant of Interest.

Variants of Concern are those whose characteristics have a significant influence on the spread of the virus — because of higher rates of contagion and rising infection rates, or an increase in severe cases of the illness and COVID mortality rates.

EG.5 is one of three variants on the WHO’s watchlist. The other two are XBB.1.5, which is largely circulating in Europe and the Americas, and XBB.1.16, which is predominant in Asia.

Eris is just a nickname for EG.5

T. Ryan Gregory, an Canadian evolutionary biologist based at the University of Guelph, Ontario, has studied the subtype EG.5.1 (Ed.: note the added “.1” which indicates this is the first version of EG.5) and posted a comment on its nickname, Eris, suggesting that the nickname may lead to some confusion as we talk more and more about the variant.

Eris is also the name of one of the largest dwarf planets in our solar system — Eris is the Greek goddess of chaos. But, notes Gregory, the nickname is unlikely to cause a big wave in itself.

COVID variant EG.5: What we know about Eris

How has EG.5 spread so far?

The WHO classified EG.5 as a VOI due to rising infection rates attributed to the variant, the fact that it spreads fast and its ability of so-called “immune escape”.

EG.5 is a descendent lineage of XBB. 1.9.2. It has an additional spike mutation that may explain why it can escape the human immune system’s response.

That’s according to the Neherlab research group, based at the Biozentrum, University of Basel, Switzerland. In a Neherlab variant report posted at the end of June 2023, EG.5 was already described as the “fastest growing lineage with significant circulation” in the world.

The report said that EG.5 “might also be a slightly beneficial mutation.”

Neherlab’s data suggests that EG.5 was first detected in February 2023 in Indonesia and the following month in the USA.

EG.5 was also on the agenda of a virtual press conference hosted by the WHO on July 27, 2023. During the briefing, Maria Van Kerkhove, the WHO’s Technical Lead for COVID-19, said “all of the variants that we are detecting that are sublineages of Omicron have an increased growth rate.”

That, said Van Kerkhove, “raises the point that this virus continues to circulate and it continues to change.”

In its EG.5 Initial Risk Evaluation report (August 7, 2023), the WHO said the variant had been sequenced more than 7,350 times, with samples from 51 countries.

Most of the variant sequences were from China, with 30.6%, or 2247 sequences. Other countries listed with at least 100 sequences included the USA, South Korea, Japan, Canada, Australia, Singapore, the UK, France, Portugal and Spain.

Why we still have to ‘keep an eye’ on COVID

At the end of July, Van Kerkhoven said “[w]e aren’t seeing the same level of impact in terms of hospitalizations and deaths because people are protected largely from vaccination but also from past infection, so we have some immunity that has been built up.”

But Van Kerkhove says there is a concern that “we could potentially see new variants that could be more severe and that’s something we have to keep an eye out for […].”

As a result, warned the epidemiologists, it’s important that nations continue to report COVID-related mortality rates, hospitalizations, cases requiring intensive. But in July, only a quarter of all nations provided the WHO with death rates, and only 11% of nations provided data on severe cases.

Continuing sequencing is also vital, said Van Kerkhove: “make no mistake, the virus has not gone away.”

It is, however, as yet unclear whether EG.5 caused the most recent rise in COVID cases. US-based physician and scientist Eric Topol said in a post that while it was important to “track the evolution” of the virus, there was “no clear [cause] and effect relationship with the current (small) increases in wastewater, cases, hospitalizations […].”

That was backed up by the WHO’s August 9 EG.5 risk assessment.

COVID-19: The seasonal effect

Despite conclusions drawn at the time of writing, the WHO sees a potential for EG.5 to “cause a rise in case incidence and become dominant in some countries or even globally” due to its “growth advantage and immune escape characteristics” — same as it was with other variants in the omicron lineage of the virus.

Right now, though, the consensus is that EG.5 is not a big threat. The rise in cases could be explained by the fact that we (in the Northern Hemisphere) are in the midst of a summertime COVID-wave. During the heat of summer, people tend to stay in air conditioned spaces. The virus continues to mutate, protection we had from previous infections diminishes, and the risk of our catching a new infection goes up.

So, it’s a good reminder for us to keep COVID-19 in view and under control. Latest reports suggest that updated COVID vaccines — for protection against new variants, including EG.5 — should be available in the coming months.

Read more at-https://shorturl.at/fCFJL

Categories
COVID-19 Government Guidelines Medical Equipments Medical Updates Medicine & Health

Eyes, allergies and monsoon: Tips on coping with seasonal eye allergies in rainy season

As the humidity rises, let’s explore the link between allergies, infections and rains and learn some essential tips to cope with pesky eye issues this monsoon

Monsoon, the much-awaited respite from scorching heat, brings with it a mix of delight and distress because while the raindrops dance merrily, our eyes often find themselves struggling to keep up with the joy as it is that time of the year again when seasonal eye allergies and infections make their unwelcome appearance. As the heavens open up and the humidity rises, let’s explore the connection between allergies, infections, the rains and discover some essential tips to cope with these pesky eye issues.

Connection between allergies and monsoon

In an interview with HT Lifestyle, Dr Vijay Mathur, Senior Consultant at Sharp Sight Eye Hospitals , shared, “Monsoon is notorious for triggering eye allergies and infections. The dampness fosters the growth of viruses and fungi, leading to conjunctivitis, commonly known as “pink eye.” Symptoms include redness, itching, grittiness and excessive tearing with discharge. Pollen, dust, and other airborne particles carried by the monsoon winds can further aggravate eye irritation, causing discomfort to even non-allergic individuals.”

Common eye-related problems in monsoon

Dr Vijay Mathur highlighted –

1. Epidemic infectious conjunctivitis: Is the leading culprit. This condition causes red, itchy, gritty and watery eyes due to infection caused by viruses (adenovirus is the most common) in the air. This condition is highly infectious and can easily transmit from one person to another. Personal hygiene including hand washing is an effective way to prevent person to person transmission.

2. Allergic conjunctivitis: Monsoon is a time when fungi and moulds multiply. This leads to allergies in susceptible individuals.

3. Styes and chalazion: The damp environment fosters bacterial growth, leading to painful styes and chalazion on the eyelids.

4. All other eye infections: Bacteria and viruses thrive in the monsoon, increasing the risk of eye infections like Keratitis and Dacrocystitis.

Coping strategies:

Bringing his expertise to the same, Dr Rishi Raj Borah, Country Director – India, Orbis, revealed, “During the monsoon season, it is essential to focus more on our eyes since the rains and increasing humidity offer an ideal environment for pathogenic organisms such as bacteria, viruses, and fungal moulds to develop and multiply. Eye conditions such as allergies and conjunctivitis are prevalent during the rainy season. They usually cause red, itchy, and watery eyes. Identifying and suppressing the root cause is the best approach to avoid all the sufferings associated with eye allergies. This means that if a person knows they are allergic to a specific substance, such as a fungal mould, they should avoid going to wet regions where they might come into contact with mould.”

Eyes, allergies and monsoon: Tips on coping with seasonal eye allergies in rainy season

He added, “Similarly, if someone is allergic to pollen, they should avoid stepping out of the house during the period when the pollen concentration is high in the air. Furthermore, wearing eyeglasses when going outside is a good practice that everyone should undertake. Maintaining personal hygiene by often washing hands with soap and water is essential. To reduce the chances of introducing irritants from the surroundings into the eyes, avoid touching the face and eyes frequently. Even when humidity levels are at their highest during the monsoon, dry eyes can occur.”

Dr Rishi Raj Borah suggested, “In such circumstances, artificial tears can assist to relieve discomfort while also moisturising the eyes. Furthermore, sharing personal belongings like towels and makeup should be avoided. It is also preferable to avoid utilising public swimming pools during the rainy season, since these might serve as breeding grounds for the spread of bacterial illnesses. Seeking professional medical assistance should be the norm for anyone experiencing symptoms of an eye allergy and if you are unsure of the underlying cause, an eye doctor or ophthalmologist will be able to help find out the probable root cause and offer therapies to relieve the symptoms.”

According to Dr Vijay Mathur, to combat these monsoon-related eye issues, follow these essential coping strategies –

1. Cleanliness first: Regularly clean your living space to reduce mold and dust accumulation.

2. Hand hygiene: Maintain good hand hygiene to prevent eye infections by refraining from touching your eyes with unwashed hands.

3. Use eye drops: Over-the-counter artificial tears provide relief from dryness and flush out allergens.

4. Stay dry: Avoid getting drenched in rain and getting splashed with dirty water in puddles to minimise exposure to allergens and infectious agents.

5. Consult your doctor: If symptoms persist, seek professional help for proper diagnosis and treatment.

With a little vigilance and proactive care, you can ensure that your eyes remain resilient during the monsoon. Welcome the rains with open arms and remember to shield your precious vision from seasonal woes.

Read more at-https://shorturl.at/psuH0

Categories
Medical Equipments Medical Updates Medicine & Health

New Covid variant EG.5: Symptoms to transmissibility; 7 things to know about Omicron subvariant Eris

Covid variant EG.5 which is also unofficially known as Eris has been declared by WHO a variant of interest and the organization has asked countries to monitor the cases. Eris has been spreading fast in UK and is adding to the number of infections. Experts, however, say there’s no need to worry as the cases are largely mild and while hospitalisation cases in elderly have slightly increase, they remain lower than earlier waves. As per WHO, Eris has been found in 51 countries, including China, the US, the Republic of Korea, Japan, Canada, Australia, Singapore, the UK, France, Portugal and Spain. The symptoms of the new Covid variant Eris are reported to be running nose, sneezing, cough, fever, fatigue among others.

“The World Health Organization has identified a new strain of Covid-19 as a noteworthy variation, despite the little risk to the general public’s health. The EG. 5 or ‘Eris’ version, which is more prevalent globally, is connected to the Omicron subvariant XBB.1.9.2. Despite EG.5’s higher prevalence, growth advantage, and immune escape traits, no changes in disease severity have been noted yet. As per availability of suggested data, there is currently no reason to believe that this wave will be worse than past waves this year, but it will likely result in a wave of more cases and all the complications that brings, including more hospitalizations and Long Covid,” says Dr Vidya S Nair, Sr. Consultant & HOD- Pulmonology at Marengo Asia Hospitals, Faridabad.

Dr Ather Pasha, Senior consultant Internal Medicine, CARE Hospitals, Banjara Hills, Hyderabad shares 7 things you want to know about Covid’s new variant Eris.

New Covid variant EG.5: Symptoms to transmissibility; 7 things to know about Omicron subvariant Eris

7 facts about EG.5 or Eris
1. Omicron’s sub-variant

Eris is a subvariant of the Omicron variant, specifically XBB.1.9.2. It was first identified in China in February 2023 and has since spread to over 50 countries.

2. Transmissibility higher?

Eris is thought to be more transmissible than previous Omicron subvariants, but it is not clear if it is more severe. Early studies suggest that Eris may cause more hospitalizations than previous Omicron subvariants, but more research is needed to confirm this.

3. Eris evades immunity gained by infection or vaccination

Eris appears to be able to evade some of the antibodies produced by previous COVID-19 infections and vaccinations. This means that people who have been previously infected or vaccinated may still be at risk of getting sick with Eris.

4. Signs and symptoms of Eris

The symptoms of Eris are similar to those of other COVID-19 variants, including fever, cough, shortness of breath, fatigue, muscle aches, headache, and sore throat. Some people with Eris may also experience a loss of taste or smell.

5. Treatment for Eris

There is no specific treatment for Eris. Treatment is supportive and includes rest, fluids, and over-the-counter medications to relieve symptoms. In some cases, hospitalization may be necessary.

6. Ways to prevent Eris

The best way to protect yourself from Eris is to get vaccinated and boosted against COVID-19. Vaccination and boosters help to protect you from getting sick, even if you do get infected.

7. Covid-appropriate behaviour

You can also protect yourself from Eris by wearing a mask, social distancing, and washing your hands frequently.

“Since vaccination is still the strongest defense against upcoming Covid-19 waves, it is crucial that everyone get all of the doses for which they are qualified as soon as possible. In India, presence of herd immunity also is going to be an added advantage as we have seen multiple waves of the Omicron variants. Long-term illness in anyone who has the infection is always a concern, as is severe disease in older adults and people with underlying problems. Therefore, every precaution should be taken (including avoiding crowded areas, wearing appropriate masking, cleaning hands, etc,” says Dr Nair.

Read more at-https://tinyurl.com/yjbprr9h